Patents by Inventor Jens-Peter Von Kries

Jens-Peter Von Kries has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Selective inhibitors of gentotoxic steress-induced IKK/NF-?B pathways
    Patent number: 11028084
    Abstract: A method is for treatment of a disease associated with genotoxic stress-induced inhibitor of nuclear factor-?B kinase/nuclear factor kappa-light chain enhancer of activated B cells (IKK/NF-?B) signaling. The method can include administering a compound to a subject having a cancer exhibiting genotoxic stress induced IKK/NF-?B activation.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: June 8, 2021
    Assignees: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft, Forschungsverbund Berlin e.V
    Inventors: Claus Scheidereit, Michael Willenbrock, Peter Lindemann, Silke Radetzki, Jens-Peter Von Kries, Marc Nazare
  • Antagonists of the thyroid-stimulating hormone receptor (TSHR)
    Patent number: 10596168
    Abstract: Chemical compounds are useful in the treatment of a subject afflicted by a thyroid disease. The compounds exhibit activity as thyroid-stimulating hormone receptor (TSHR) antagonists and can be used in the treatment of hyperthyroidism, Graves' disease, Graves' Ophthalmopathy and thyroid cancer.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: March 24, 2020
    Assignee: Forschungsverbund Berlin e.V.
    Inventors: Gerd Krause, Inna Hoyer, Edgar Specker, Jens Furkert, Patrick Marcinkowski, Jens-Peter Von Kries, Martin Neuenschwander, Marc Nazare
  • SELECTIVE INHIBITORS OF GENTOTOXIC STERESS-INDUCED IKK/NF-KB PATHWAYS
    Publication number: 20190276452
    Abstract: A method is for treatment of a disease associated with genotoxic stress-induced inhibitor of nuclear factor-?B kinase/nuclear factor kappa-light chain enhancer of activated B cells (IKK/NF-?B) signaling. The method can include administering a compound to a subject having a cancer exhibiting genotoxic stress induced IKK/NF-?B activation.
    Type: Application
    Filed: November 14, 2017
    Publication date: September 12, 2019
    Inventors: Claus Scheidereit, Michael Willenbrock, Peter Lindemann, Silke Radetzki, Jens-Peter Von Kries, Marc Nazare
  • ANTAGONISTS OF THE THYROID-STIMULATING HORMONE RECEPTOR (TSHR)
    Publication number: 20190134024
    Abstract: Chemical compounds are useful in the treatment of a subject afflicted by a thyroid disease. The compounds exhibit activity as thyroid-stimulating hormone receptor (TSHR) antagonists and can be used in the treatment of hyperthyroidism, Graves' disease, Graves' Ophthalmopathy and thyroid cancer.
    Type: Application
    Filed: April 26, 2017
    Publication date: May 9, 2019
    Applicant: Forschungsverbund Berlin e.V.
    Inventors: Gerd KRAUSE, Inna HOYER, Edgar SPECKER, Jens FURKERT, Patrick MARCINKOWSKI, Jens-Peter VON KRIES, Martin NEUENSCHWANDER, Marc NAZARE
  • Agents for treating human illnesses based on ?-catenin, and the production and use thereof
    Patent number: 7067474
    Abstract: The present invention relates to peptides that affect the interaction of the protein ?-catenin with a transcription factor or a tumor suppressor protein. Such peptides are derived either from the amino acids of ?-catenin that are known to interact with such proteins, or from the amino acids of the transcription factor or tumor suppressor protein that are known to interact with ?-catenin. The effect of the interaction is preferably inhibition of binding of ?-catenin and the transcription factor or tumor suppressor protein. Peptide mutants and peptidomimetic compounds are also contemplated in the invention. The peptides, mutands and peptidomimetic compounds of the invention are useful for treating cancer in mammals, and particularly in humans.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: June 27, 2006
    Assignee: Max-Delbruck-Centrum fur Molekulare Medizin
    Inventors: Walter Birchmeier, Jens-Peter Von Kries